**Supplementary Table.** Clinical characteristics of MS patients with lab-confirmed COVID receiving OCR vs Non-OCR by Race/ Ethnicity

|  |  |  |
| --- | --- | --- |
|  | **OCR** | **Non-OCR** |
|  | **Whiten=27** | **AAn=14** | **HAn=23** | **Othern=6** | **Total****n=70** | **Whiten=42** | **AAn=35** | **HAn=26** | **Othern=5** | **Total****n=107** |
| Age, years |  |  |  |  |  |  |  |  |  |  |
| Mean (SD) | 42.2(9.6) | 37.6(8.7) | 34.4(7.4) | 32.3(13.3) | 37.9(9.7) | 43.9(11.4) | 41.1(10.9) | 37.8(10.8) | 37.3(17.2) | 41.3(11.4) |
| Sex, n (%) |  |  |  |  |  |  |  |  |  |  |
| Female | 22(81.5) | 9(64.3) | 17(73.9) | 5(83.3) | 53(75.7) | 20(47.6) | 29(82.9) | 19(73.1) | 4(100) | 72(67.3) |
| Ambulatory status, n (%) |  |  |  |  |  |  |  |  |  |  |
| Fully ambulatory | 23(85.2) | 8(57.1) | 14(60.9) | 5(83.3) | 50 (71.4) | 31(73.8) | 22(62.9) | 22(84.6) | 2(50.0) | 77(72.0) |
| COVID Symptom count, n (%) |  |  |  |  |  |  |  |  |  |  |
| 0  | 5 (18.5) | 3 (21.4) | 8 (34.8) | 3 (50.0) | 19 (27.1) | 7 (16.7) | 11 (31.4) | 5 (19.2) | 1 (25.0) | 24 (22.4) |
| 1-3 | 5 (18.5) | 7 (50.0) | 4 (17.4) | 1 (16.7) | 17 (24.3) | 8 (19.0) | 4 (11.4) | 10 (38.5) | 2 (50.0) | 24 (22.4) |
|  >3 | 17 (63.0) | 4 (28.6) | 11 (47.8) | 2 (33.3) | 34 (48.6) | 27 (64.3) | 20 (57.2) | 11 (42.3) | 1 (25.0) | 59 (55.2) |
| Respiratory symptoms, n (%) | 5 (18.5) | 3 (21.4) | 8 (34.8) | 0 | 16 (22.9) | 16 (38.1) | 11 (31.4) | 11 (42.3) | 0 | 38 (35.5) |
| Hospitalization, n (%) | 1 (3.7) | 1 (7.1) | 0 | 0 | 2 (2.9) | 4 (9.5) | 2 (5.7) | 1 (3.8) | 0 | 7 (6.5) |
| Infection to collection, weeks |  |  |  |  |  |  |  |  |  |  |
| n | 22 | 7 | 12 | 3 | 44 | 31 | 23 | 15 | 3 | 72 |
| Mean (SD) | 26.8(19.0) | 23.2(16.3) | 26.2(19.0) | 36.0(22.4) | 26.7(18.4) | 36.6(18.4) | 45.6(13.5) | 41.3(17.1) | 6.9(1.0) | 39.2 (17.9) |
| Median (Q1, Q3) | 16.9(9.6, 46.1) | 13.7(12.0, 42.4) | 20.1(10.9, 46.1) | 43.0(11.0, 54.1) | 18.0 (11.1, 45.6) | 44.7(15.0, 51.4) | 49.1(44.1, 53.0) | 47.9(24.7, 51.6) | 6.4(6.1, 8.0) | 46.4 (19.8, 51.6) |
| Log of Elecsys anti-SARS-CoV-2 Ab |  |  |  |  |  |  |  |  |  |  |
| n | 26 | 14 | 23 | 6 | 69 | 36 | 29 | 23 | 4 | 92 |
| Mean (SD) | 0.3a(0.6) | 0.5(0.9) | 0.3(0.5) | 0.0(0.0) | 0.3 (0.6) | 1.6b(0.9) | 1.9c(0.8) | 1.4d(1.1) | 1.5(1.1) | 1.6 (0.9) |
| Median (Q1, Q3) | 0.0(0.0, 0.8) | 0.0(0.0, 0.6) | 0.0(0.0, 0.6) | 0.0(0.0, 0.0) | 0.0 (0.0, 0.6) | 1.7(0.8, 2.2) | 2.1(1.4, 2.3) | 1.6(0.0, 2.2) | 1.7(0.5, 2.4) | 1.8 (1.0, 2.2) |
| Log of MBI IgG Sspike Ab |  |  |  |  |  |  |  |  |  |  |
| n | 27 | 14 | 23 | 6 | 70 | 42 | 35 | 26 | 4 | 107 |
| Mean (SD) | 3.0(0.9) | 3.3(0.9) | 3.0(0.9) | 2.7(0.3) | 3.0 (0.9) | 3.7(0.5) | 3.9(0.4) | 3.6(0.7) | 3.5(1.4) | 3.7 (0.6) |
| Median (Q1, Q3) | 3.0(2.5, 3.7) | 3.4(2.4, 4.3) | 3.2(2.4, 3.9) | 2.6(2.5, 3.0) | 2.6 (2.5, 3.0) | 3.8(3.4, 4.1) | 4.0(3.7, 4.3) | 3.8(3.3, 4.0) | 4.1(2.6, 4.3) | 3.9(3.4, 4.2) |
| Log of Nabs ID50 |  |  |  |  |  |  |  |  |  |  |
| n | 16 | 5 | 9 | 2 | 32 | 22 | 11 | 10 | 2 | 45 |
| Mean (SD) | 1.3e(0.5) | 1.5f(0.7) | 1.6g(0.5) | 1.0h(0.0) | 1.4 (0.5) | 2.1i(0.7) | 1.8j(0.8) | 1.8k(0.3) | 2.5l(0.1) | 2.0 (0.6) |
| Median (Q1, Q3) | 1.0(1.0, 1.5) | 1.0(1.0, 1.9) | 1.4(1.3, 2.0) | 1.0(1.0, 1.0) | 1.1 (1.0, 1.8) | 2.4(1.6, 2.5) | 1.9(1.4, 2.3) | 1.9(1.6, 2.0) | 2.5(2.4, 2.5) | 1.9(1.6, 2.5) |
| Log of TruCulture IFN |  |  |  |  |  |  |  |  |  |  |
| n | 25 | 14 | 22 | 6 | 67 | 35 | 29 | 24 | 4 | 92 |
| Mean (SD) | 1.2 (0.9) | 0.8 (1.2) | 1.2 (1.0) | 0.3 (0.5) | 1.0 (1.0) | 1.4 (1.1) | 1.5 (1.1) | 1.0 (1.2) | 1.4 (1.6) | 1.3 (1.1) |
| Median (Q1, Q3) | 1.3 (0.0, 1.7) | 0.0 (0.0, 1.9) | 1.3(0.0, 1.8) | 0.0(0.0, 0.3) | 1.2(0.0, 1.8) | 1.7(0.0, 2.4) | 1.5(0.8, 2.3) | 0.0(0.0, 1.9) | 1.3(0.0, 2.8) | 1.4(0.0, 2.4) |
| Log of TruCulture IL2 |  |  |  |  |  |  |  |  |  |  |
| n | 25 | 14 | 22 | 6 | 67 | 35 | 29 | 24 | 4 | 92 |
| Mean (SD) | 0.5 (0.8) | 0.8 (1.1) | 0.7 (0.9) | 0.3 (0.6) | 0.6 (0.9) | 0.9 (1.0) | 1.0 (1.0) | 0.8 (0.9) | 0.8 (0.8) | 0.9 (0.9) |
| Median (Q1, Q3) | 0.0(0.0, 1.0) | 0.0(0.0, 1.7) | 0.2(0.0, 1.5) | 0.0(0.0, 0.0) | 0.0(0.0, 1.3) | 1.0(0.0, 1.7) | 1.2 (0.0, 1.9) | 0.0(0.0, 1.7) | 0.5(0.2, 1.3) | 0.7 (0.0, 1.8) |

Ab, antibodies; AA, African American; HA, Hispanic American; OCR, ocrelizumab.